水痘疫苗预先设定不良事件的评估:一项基于人群的自身对照风险区间研究
该研究基于台湾地区2004至2014年全民健康保险与免疫信息系统数据,纳入1,194,189名12-35月龄接种单剂水痘疫苗的儿童,采用自身对照风险区间设计比较接种后1-42天风险区间与43-84天对照区间内肺炎、免疫性血小板减少性紫癜(ITP)、脑膜炎、脑炎及缺血性卒中的发生率。结果显示ITP、脑膜炎、脑炎、缺血性卒中风险未见升高,但肺炎在接种后36-42天出现聚集(aIRR 1.10;95% CI,1.02-1.18);同时接种水痘疫苗与MMR疫苗的儿童ITP风险升高(aIRR 1.70;95% CI,1.19-2.43),而仅接种水痘疫苗者未见升高。
要点
- 接种后1-42天与43-84天相比,ITP、脑膜炎、脑炎、缺血性卒中风险未见升高。
- 肺炎在接种后36-42天出现聚集,aIRR 1.10(95% CI,1.02-1.18)。
- 同时接种水痘疫苗与MMR疫苗者ITP风险升高(aIRR 1.70;95% CI,1.19-2.43)。
核心结论
- 检测到水痘疫苗免疫后第6周与偶发肺炎相关的微小风险。
- 其他预先设定不良事件的风险未见升高。
研究设计与样本
- 全国性观察性研究,基于台湾地区全民健康保险数据与免疫信息系统,覆盖2004年至2014年。
- 主要分析纳入在接种日期接种单剂水痘疫苗的12-35月龄儿童,共1,194,189名。
- 采用自身对照风险区间设计,比较接种后1-42天风险区间与43-84天对照区间内预先设定结局的发生率。
- 采用条件泊松回归评估调整年龄与季节效应后的发生率比(aIRR)。
主要发现
- ITP的aIRR为1.00(95% CI,0.76-1.33)。
- 脑膜炎的aIRR为1.21(95% CI,0.49-2.95)。
- 脑炎的aIRR为1.00(95% CI,0.62-1.60)。
- 缺血性卒中的aIRR为1.24(95% CI,0.31-4.95)。
- 肺炎在接种后36-42天出现聚集,aIRR为1.10(95% CI,1.02-1.18)。
关键数值与推荐
- 结局定义包括入院肺炎、ITP、脑膜炎、脑炎、缺血性卒中,以及作为阴性对照的骨折。
- 风险区间为接种后1-42天,对照区间为接种后43-84天。
- 调整因素包括年龄与季节效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical trials and spontaneous reporting systems have revealed rare but biologically plausible adverse events following varicella immunization. Few post-marketing controlled studies have been conducted to assess the relationship between the varicella vaccine and these outcomes. OBJECTIVES: To evaluate the risk of pneumonia, idiopathic thrombocytopenic purpura (ITP), meningitis, encephalitis and ischemic stroke following varicella immunization. MATERIALS AND METHODS: This nationwide observational study was based on Taiwan National Health Insurance data and National Immunization Information System from 2004 through 2014. Primary analysis included children aged 12-35 months who received the single varicella vaccine on the date of administration. The self-controlled risk interval design compared the incidence of pre-specified outcomes during a risk interval of 1-42 days post-vaccination and a control interval of 43-84 days. The outcomes of interest were defined as admitted pneumonia, ITP, meningitis, encephalitis, and ischemic stroke, as well as fracture as a negative control. Conditional Poisson regression was used to assess the incidence rate ratio (aIRR) with adjustments for age and seasonal effects. RESULTS: Among 1,194,189 children, who receiving the varicella vaccine, there was no observed increase in the risk for ITP (aIRR 1.00; 95% CI, 0.76-1.33), meningitis (aIRR 1.21; 95% CI, 0.49-2.95), encephalitis (aIRR 1.00; 95% CI, 0.62-1.60), or ischemic stroke (aIRR 1.24; 95% CI, 0.31-4.95). A clustering feature with pneumonia occurred during days 36-42 post-vaccination (aIRR 1.10; 95% CI, 1.02-1.18). An increase in the risk for ITP was observed in children receiving the varicella and MMR vaccines concomitantly (aIRR 1.70; 95% CI, 1.19-2.43), but not among those receiving the varicella vaccine only. CONCLUSIONS: We detected a small risk of incidental pneumonia associated with varicella vaccine in the 6th week after immunization. There was no increase in the risk of other pre-specified adverse events.
引用
- Liu CH, Yeh YC, Huang WT, et al. Assessment of pre-specified adverse events following varicella vaccine: A population-based self-controlled risk interval study. Vaccine. 2020. PMID: 32046891. doi:10.1016/j.vaccine.2020.01.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。